ClinicalTrials.gg
RecruitingNCT06586905Updated Nov 18, 2025

A Cross-sectional Investigational Study to Evaluate the Sensitivity, Specificity, and Utility of the MedMira Inc. Multiplo® Complete Syphilis (TP/nTP) Antibody Test (POCT) to Diagnose Infectious Syphilis in Participants Attending the Sexual Health Clinic in Ottawa, Ontario.

An interventional study of Medical Device in Syphilis and Treponema Pallidum, sponsored by MedMira Laboratories Inc.. Recruiting at 1 site in Canada. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by MedMira Laboratories Inc. · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
1,300
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Study summary

Due to the recent resurgence of infectious syphilis in Canada and the changing epidemiology of the disease to involve heterosexuals and females of child bearing age leading to a record number of congenital syphilis cases and stillbirths, the demand of a rapid test such as POCT that can be used at the place and time that front-line public health workers meet the at risk population is getting louder. Indeed during a number of federal, provincial and territorial meetings on the control of syphilis outbreaks in Canada, requests for POCT to detect syphilis infections have repeatedly come up. However, before a POCT can be widely used, research to find out if it is accurate and reliable is necessary. This study is designed to test the performance of the MedMira Inc. Multiplo® Complete Syphilis (TP/nTP) Antibody Test (POCT) (MedMira Inc., Halifax, Nova Scotia) in an urban clinic (Sexual Health Clinic) in Ottawa, Ontario, Canada and compare its performance in parallel with the usual testing method (the gold standard, i.e. conventional syphilis serology testing).

02

Conditions studied

  • Syphilis
  • Treponema Pallidum

Browse trials for

Keywords

  • Syphilis
  • TP/nTP
  • Multiplo Complete Syphilis (TP/nTP) Antibody Test
  • MedMira
  • Treponema pallidum
  • rapid test
  • point of care
03

In context

Syphilis

126 studies on the registry are indexed under Syphilis; 34 are open to participants now.

This study's planned enrollment of 1,300 is above the median of 354 across 85 interventional studies indexed under Syphilis.

Browse Syphilis studies →

Lead sponsor

MedMira Laboratories Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals attending the Clinic for routine sexual health care and requiring syphilis testing as part of this care, who are able to provide and are a minimum 16 years of age are eligible for this study. This includes patients attending the Clinic for follow-up appointments following diagnosis with syphilis infection. Those who have had other STIs in the past, or being suspected of having other STIs, are not excluded as long as testing for syphilis is part of the care provided to them. Once it has been determined that the exclusion criteria does not apply to a patient, the recruitment of participants will be offered without other pre-selection criteria unless there may be other unforeseeable circumstances arising, such as shortage of Clinic staff or large numbers of patients in attendance.

Exclusion criteria

Exclusion Criteria:

  • Those who, at the discretion of the HCPs/research co-ordinator, appear intoxicated and/or with extreme distress, or confused, will be excluded from this research because they would not be able to provide to participate, as well as those below the age of 16 years.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,300 participants (estimated)

Study arms

  • Experimental
    Multiplo Complete Syphilis (TP/nTP) Antibody Test

    Participants are tested with investigational devices and conventional syphilis serology tests

    Device: Medical Device

Interventions

  • DeviceMedical Device

    Multiplo Complete Syphilis (TP/nTP) Antibody Test

06

What researchers measure

Primary outcomes

  1. To determine the accuracy of Multiplo Complete Syphilis (TP/nTP) Antibody Test

    For each enrolled subject, Multiplo Complete Syphilis (TP/nTP) Antibody Test will be used to test fingerstick whole blood from the patient. A venipuncture whole blood sample will also be drawn from the patient and will be tested using conventional serological testing methods to determine patient status.

    Time frame: 1 patient visit of appoximately 30 minutes

07

Study locations

1 of 1 sites recruiting
  • Sexual Health Clinic
    Ottawa, Ontario K1N 1B3, Canada
    Recruiting
    • Patrick O Byrne · Contactpatrick.obyrne@uottawa.ca · (613) 234-4641
    • Lauren Orser · Contact
    • Patrick O Byrne · Principal investigator
08

References and documents

Publications

  • O'Byrne P, Dillabough R, Whyte K, Orser L, Tran V, Duvvuri VR, Tsang R. Evaluating the MedMira Multiplo(R) Complete Syphilis (TP/nTP) antibody test in a sexually transmitted infection clinic in Ottawa, Canada: increased rapid diagnosis and improved antibiotic stewardship. BMC Infect Dis. 2025 Dec 8;26(1):48. doi: 10.1186/s12879-025-12263-w. PubMed 41361278 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06586905
Lead sponsor
MedMira Laboratories Inc.
Collaborators
Public Health Agency of Canada (PHAC)
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Aug 26, 2024
Primary completion
Jan 31, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
Nov 18, 2025

Study contacts

Jennifer MacLellan
Contact
support@medmira.com
902-450-1588
Kayla Turner
Contact
902-450-1588

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion